Table 1.

Patient clinical characteristics

Patient	Age, yr	Sex	MH	Medications	Evidence of systemic IgA vasculitis before vaccination	Temporal relation of gross hematuria to Moderna SARS-CoV-2 mRNA vaccination	Baseline (hematuria / uPCR / SCr)	Presentation (hematuria / uPCR / SCr)	Evidence of systemic IgA vasculitis after vaccination	Biopsy	Treatment	Follow-up 1 mo post second dose (hematuria / uPCR / SCr)
1	22	F	None	None since episodic steroids for IgA vasculitis at age 10 yr	Yes	48 h after second dose	4–10 / neg / 0.80	>50 / 0.40 / 0.80	No	No	None	0–3 / 0.27 / 0.80 (hematuria returned to baseline)
2	39	F	None	None	No	48 h after second dose	0–3 / neg / no baseline	>50 / 0.90 / 0.80	No	No	None	0 / below detection / 0.80 (hematuria and proteinuria returned to baseline)
3	50	M	HTN	None	No	24 h after second dose	11–25 / 2.40 / 1.17	>50 / 3.56 / 1.54	No	Yes, kidney	RAASi	11–25 / 2.20 / 1.24 (hematuria and proteinuria returned to baseline; SCr improving but above baseline)
4	67	M	HTN	RAASi	No	1 mo after first dose	0–3 / 0.05 / 1.20	>50 / 2.10 / 2.90	Yes, bilateral lower extremity maculopapular rash	Yes, skin	Steroid	0–3 / 0.09 / 1.40 (hematuria and proteinuria returned to baseline; SCr improving but above baseline)

F, female; HTN, hypertension; M, male; neg, negative; MH, medical history; RAASi, renin-angiotensin-aldosterone system inhibition; SCr, serum creatinine (in mg/dL); uPCR, urine protein-to-creatinine ratio.

Hematuria is expressed as number of red blood cells per high-powered field on urinalysis. None of the patients had episodes of gross hematuria before vaccination, and none were known to have been infected with SARS-CoV-2, although serologic testing before vaccination was not performed.